在2024年治疗长音声症:一个范围审查
Ralph Haddad1, Estelle Bogdanski1, Alexia Mattei1
1Department of Oto-Rhino-Laryngology and Head and Neck Surgery, AP-HM, Marseille, La Conception University Hospital, Aix-Marseille University, 147 Boulevard Baille, CEDEX 5, 13385 Marseille, France.
Journal of voice : official journal of the Voice Foundation
|December 31, 2024
概括
长音声症的治疗需要一个全面的方法,解决整体健康和特定的声问题. 最初建议进行语音疗法,在严重病例中进行办公室式媒介,以改善语音质量.
科学领域:
- 老年学是一门学科.
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 语音语言病理学 语言病理学
背景情况:
- 长音声症是一种与年龄相关的语音障碍,具有复杂的多因素挑战.
- 有效的管理需要解决系统衰老因素和喉功能障碍.
- 老年人的虚弱和药物的副作用可能会加剧声音的变化.
研究的目的:
- 概述一个全面的,以证据为基础的治疗策略,对presbyphonia.
- 提出一个分层治疗方法,优先考虑非侵入性干预.
- 为了确定最佳的干预措施,以关闭喉隙和声柔性.
主要方法:
- 进行了一项文献范围审查,以综合有关长音声症管理的当前证据.
- 审查的重点是确定有效的语音疗法和最少侵入性的喉手术.
- 治疗建议是根据患者的声音需求和状隙的严重程度制定的.
主要成果:
- 语音治疗,包括各种练习,被提议作为提高语音质量的首要治疗方法.
- 建议在办公室使用注射氨酸的介质化作为一线干预措施,用于显著的喉间隙或高声需求.
- 富于血小板的血注射可以补充介质化,以改善粘膜的振动功能.
结论:
- 一个整体的管理策略,结合全球健康优化和向的喉治疗,对于大声症至关重要.
- 一个逐步的方法,从语音治疗开始,到办公室的媒体化,提供了一个量身定制的治疗途径.
- 微创手术,如 Hyaluronic 酸和 PRP 注射,提供有效的选择,以改善声功能在长音声症.
相关概念视频
01:23Chronic Pharyngitis
505
Chronic pharyngitis refers to persistent inflammation of the pharyngial mucosa.
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
505
01:31Hearing
51.1K
When we hear a sound, our nervous system is detecting sound waves—pressure waves of mechanical energy traveling through a medium. The frequency of the wave is perceived as pitch, while the amplitude is perceived as loudness.
51.1K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
85
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
85
01:27Open Angle Glaucoma: Treatment
355
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
355
01:28Angle Closure Glaucoma: Treatment
360
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
360
01:20Myasthenia Gravis: Overview and Treatment
932
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
932